BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 25683228)

  • 1. Uveitic macular oedema after treatment with vemurafenib.
    Fonollosa A; Mesquida M; Adan A
    Acta Ophthalmol; 2015 Dec; 93(8):e686-7. PubMed ID: 25683228
    [No Abstract]   [Full Text] [Related]  

  • 2. Bilateral panuveitis in a patient on vemurafenib BRAF inhibitor therapy for stage IV melanoma.
    Agemy SA; Mehta AN; Pachydaki SI; Tewari A
    Eur J Ophthalmol; 2014; 24(4):629-32. PubMed ID: 24474376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of the vitreomacular interface on the efficacy of intravitreal therapy for uveitis-associated cystoid macular oedema.
    Munk MR; Ram R; Rademaker A; Liu D; Setlur V; Chau F; Schmidt-Erfurth U; Goldstein DA
    Acta Ophthalmol; 2015 Nov; 93(7):e561-7. PubMed ID: 25708777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravitreal triamcinolone acetonide versus combined intravitreal bevacizumab and dexamethasone in diffuse diabetic macular oedema.
    Sheth S; Rush R; Natarajan S; Gillies M
    Clin Exp Ophthalmol; 2011; 39(7):673-81. PubMed ID: 22452685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RASopathic alopecia: hair changes associated with vemurafenib therapy.
    Piraccini BM; Patrizi A; Fanti PA; Starace M; Bruni F; Melotti B; Misciali C; Dika E
    J Am Acad Dermatol; 2015 Apr; 72(4):738-41. PubMed ID: 25773419
    [No Abstract]   [Full Text] [Related]  

  • 6. Multiple white cysts on face and trunk of a melanoma patient treated with vemurafenib.
    Gebhardt C; Staub J; Schmieder A; Goerdt S; Utikal J
    Acta Derm Venereol; 2015 Jan; 95(1):96-7. PubMed ID: 24710689
    [No Abstract]   [Full Text] [Related]  

  • 7. Uveitis in patients with late-stage cutaneous melanoma treated with vemurafenib.
    Guedj M; Quéant A; Funck-Brentano E; Kramkimel N; Lellouch J; Monnet D; Longvert C; Gantzer A; Brézin AP
    JAMA Ophthalmol; 2014 Dec; 132(12):1421-5. PubMed ID: 25125216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abrupt development of Dupuytren's contractures with the BRAF inhibitor vemurafenib.
    Sibaud V; Chevreau C
    Joint Bone Spine; 2014 Jul; 81(4):373-4. PubMed ID: 24468667
    [No Abstract]   [Full Text] [Related]  

  • 9. Ocular toxicity in BRAF mutant cutaneous melanoma patients treated with vemurafenib.
    Choe CH; McArthur GA; Caro I; Kempen JH; Amaravadi RK
    Am J Ophthalmol; 2014 Oct; 158(4):831-837.e2. PubMed ID: 25036880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vemurafenib-induced DRESS.
    Wenk KS; Pichard DC; Nasabzadeh T; Jang S; Venna SS
    JAMA Dermatol; 2013 Oct; 149(10):1242-3. PubMed ID: 23986488
    [No Abstract]   [Full Text] [Related]  

  • 11. Iluvien Implantation for Uveitis and Uveitic Macular Edema.
    Reddy AK; Burkholder BM; Khan IR; Thorne JE
    Ocul Immunol Inflamm; 2018; 26(2):315-316. PubMed ID: 27736275
    [No Abstract]   [Full Text] [Related]  

  • 12. Tomographic assessment of therapeutic response to uveitic macular oedema.
    Sivaprasad S; Ikeji F; Xing W; Lightman S
    Clin Exp Ophthalmol; 2007 Nov; 35(8):719-23. PubMed ID: 17997774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histopathological features of cutaneous drug reactions to vemurafenib: a report of two cases.
    Dabner M; Harvey NT; Soma A; Wood BA
    Pathology; 2012 Dec; 44(7):661-4. PubMed ID: 23172086
    [No Abstract]   [Full Text] [Related]  

  • 14. Vemurafenib-Induced Disseminated Intravascular Coagulation in Metastatic Melanoma.
    van den Brom RR; Mäkelburg AB; Schröder CP; de Vries EG; Hospers GA
    J Clin Oncol; 2015 Dec; 33(36):e133-4. PubMed ID: 24778390
    [No Abstract]   [Full Text] [Related]  

  • 15. Intravitreal triamcinolone acetonide for the treatment of immune recovery uveitis macular edema.
    Morrison VL; Kozak I; LaBree LD; Azen SP; Kayicioglu OO; Freeman WR
    Ophthalmology; 2007 Feb; 114(2):334-9. PubMed ID: 17270681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Severe pan-uveitis in a patient treated with vemurafenib for metastatic melanoma.
    Wolf SE; Meenken C; Moll AC; Haanen JB; van der Heijden MS
    BMC Cancer; 2013 Dec; 13():561. PubMed ID: 24289205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vemurafenib and cutaneous adverse events--report of five cases.
    Silva Gde B; Mendes AP; de Macedo MP; Pinto CA; Gibbons IL; Duprat Neto JP
    An Bras Dermatol; 2015; 90(3 Suppl 1):242-6. PubMed ID: 26312729
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vemurafenib-induced bilateral facial palsy.
    Shailesh FN; Singh M; Tiwari U; Hutchins LF
    J Postgrad Med; 2014; 60(2):187-8. PubMed ID: 24823520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toxic epidermal necrolysis induced by vemurafenib.
    Lapresta A; Dotor A; González-Herrada C
    Actas Dermosifiliogr; 2015 Oct; 106(8):682-3. PubMed ID: 26051238
    [No Abstract]   [Full Text] [Related]  

  • 20. Structural and functional outcomes after treatment of uveitic macular oedema: an optical coherence tomography and multifocal electroretinogram study.
    Georgiadou E; Moschos MM; Margetis I; Chalkiadakis J; Markomichelakis NN
    Clin Exp Optom; 2012 Jan; 95(1):89-93. PubMed ID: 22098256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.